Renal toxicity of lisinopril and rosuvastatin, alone and in combination, in wistar rats

International Journal of Toxicology

Volumn 30, Issue 5, 2011, Pages 518-527

  Dodiya, Hardik ^a   Jain, Mukul ^b   Goswami, Sunita S ^a  

^a L M COLLEGE OF PHARMACY   (India)

^b ZYDUS RESEARCH CENTRE   (India)

Author keywords

glomerular injury; lisinopril; renal tubular injury; rosuvastatin; urinary biomarkers

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CLUSTERIN; CREATININE; LISINOPRIL; ROSUVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE; KIDNEY TUBULE DAMAGE; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; RAT; URINARY EXCRETION; URINE LEVEL;

ACUTE KIDNEY INJURY; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; CLUSTERIN; DRUG COMBINATIONS; FEMALE; FLUOROBENZENES; KIDNEY TUBULES, PROXIMAL; LISINOPRIL; PYRIMIDINES; RATS; RATS, WISTAR; SULFONAMIDES;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 80054801890     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811415293     Document Type: Conference Paper

References (16)

1. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of Acute Kidney Injury. Ann Rev Pharmacol Toxicol. 2008 ; 48: 463-493 (Pubitemid 351738161)
2. Kamala M. It is time to implement an early renal toxicity biomarker strategy. J Pharm Agrochem Chem Res. 2009 ; 9 (2). 10-12
3. Tiwari A. An overview of statin-associated protenuria. Drug Discov Today. 2006 ; 11 (9-10). 458-464
4. Zoja C, Corna D, Gagliardini E, et al. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol. 2010 ; 299 (5). F1203 - F1211
5. Cinnoti GA, Zucchelli PC. Effect of lisinopril on the pregression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant. 2001 ; 16 (5). 961-966 (Pubitemid 32440368)
6. www.fda.gov/ohrms/dockets/ac/03/briefing/3968b1-02-AFDA- Clinical%20Review.pdf
7. www.asterazeneca/documents/productportfolio/Zestril-PM-en.pdf
8. Kawamura M, Imanishi M, Matsushima Y, et al. A comparision of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans. Jpn J Pharmacol. 1990 ; 54 (2). 143-149 (Pubitemid 20329703)
9. www.fda.gov/cder/foi/nda/2003/21-366-Crestor.htm
10. Kolaja GJ, Packwood WH, Bell RR, et al. Renal Papillary necrosis and urine protein alterations induced in Fischer-344 rats by D-Ormaplatin. Toxicol Pathol. 1994 ; 22 (1). 29-38 (Pubitemid 24139626)
11. Birn H, Roger SD. Albuminuria-chasing the message, not the messanger. Port J Nephrol Hypert. 2009 ; 23 (3). 215-218
12. Jalal S, Sofi FA. Abass SM, et al. Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: a prospective study. 2010 ; 20 (1). 15-20
13. Walker R, Edwards C Acute Renal Failure. Clinical Pharmacy & Therapeutics. 2 nd ed. London, England: Churchill Livingstone; 2008:21-34. London, England: Churchill Livingstone ; 2008: 21-34.
14. Verhulst A, Sayer R, De Broe ME, DHaese PC, Brown CD. Human proximal tubular epithelium actively secretes does not retain rosuvastatin. Mol Pharmacol. 2008 ; 74 (4). 1084-1091
15. Sidaway JE, Davidson RG, Mctaggart F, et al. Inhibitors of 3-hydroxyl-3-methyl glutaryl-Co A reductase reduce receptor-mediated endocytosis in Opossum kidney cells. J Am Soc Nephrol. 2004 ; 15 (9). 2258-2265 (Pubitemid 39159326)
16. Kramer S, Kron S, Wang-Rosenke Y, et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis. Am J Physiol Renal Physiol. 2008 ; 294 (4). F801 - F811